FDA Approves Lisraya as First Oral Treatment for Adult Dermatomyositis
Regulators cited phase 3 VALOR data showing sustained muscle and skin benefit, with the drug’s label carrying a boxed warning for serious infections, cardiovascular events, cancer, and thrombosis.
